CurrentCardio
Get Weekly

Cardiovascular journalCurrentCardio coverage

European Heart Journal – Cardiovascular Pharmacotherapy

What CurrentCardio has captured from this journal. The coverage figures describe CurrentCardio's coverage, not the journal's output. Figures as of 13 October 2026.

Recent
9 Briefs
past 90 days
Archive
31 Briefs
research published Jan–Dec 2026
Editorial
–
no Weekly issue published yet
Impact Factor
8.2
2025 · Journal Citation Reports

Topics

Evidence types

Shares are of the 31 Briefs CurrentCardio has covered from Eur Heart J Cardiovasc Pharmacother, by primary topic and study type.

Publication activity

Latest from European Heart Journal – Cardiovascular Pharmacotherapy

All coverage, newest first

  1. Eur Heart J Cardiovasc Pharmacother

    Analysis and Interpretation of a Hierarchical Outcome in a Small Pilot Randomized Trial: An Example in the CORTAHF Trial

    Randomised controlled trialHeart failure

  2. Eur Heart J Cardiovasc Pharmacother

    Average daily ischemic and bleeding risk following acute coronary syndrome: Insights from the FORCE-ACS registry

    Cohort studyCoronary & ACS

  3. Eur Heart J Cardiovasc Pharmacother

    Coated or chewable aspirin and a hybrid air pollution mitigation strategy in patients with atherosclerotic disease: rationale and design of the COATED-AIR randomized trial

    Trial designCoronary & ACS

  4. Eur Heart J Cardiovasc Pharmacother

    Real-world analysis of adherence, persistence, and outcomes in patients receiving four-drug antihypertensive therapy

    Cohort studyHypertension

  5. Eur Heart J Cardiovasc Pharmacother

    Switching to angiotensin receptor–neprilysin inhibitor and reduced risk of new-onset atrial fibrillation in heart failure with reduced ejection fraction: a nationwide propensity score–matched study

    Research articleHeart failure

  6. Eur Heart J Cardiovasc Pharmacother

    Sacubitril/valsartan and cardiac injury/stress and systemic inflammatory biomarkers in acute heart failure: a pre-specified secondary analysis of the PREMIER study

    Randomised controlled trialHeart failure

  7. Eur Heart J Cardiovasc Pharmacother

    Eplerenone vs. spironolactone in heart failure: long-term cardiorenal and mortality outcomes in a registry-based cohort

    Cohort studyHeart failure

  8. Eur Heart J Cardiovasc Pharmacother

    Vagal activity-related events and glucagon-like peptide-1 receptor agonists

    Research articleCardiometabolic & kidney

  9. Eur Heart J Cardiovasc Pharmacother

    Clinical and experimental insights into hydroxychloroquine-associated electrical abnormalities and cardiomyopathy

    Research articleHeart failure

  10. Eur Heart J Cardiovasc Pharmacother

    Statin adherence among patients with hypertension in Swedish primary health care: a QregPV cohort study using explainable machine learning

    Cohort studyPrevention & lipids

  11. Eur Heart J Cardiovasc Pharmacother

    API-CAT investigators’ decisions on anticoagulation following extended treatment for cancer-associated thrombosis

    Cohort studyCardio-oncology & other

  12. Eur Heart J Cardiovasc Pharmacother

    Semaglutide for primary prevention of major adverse cardiac and cerebrovascular events in patients with type 2 diabetes and comorbid rheumatoid arthritis: a target-trial emulation

    Cohort studyCardiometabolic & kidney

  13. Eur Heart J Cardiovasc Pharmacother

    Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio–renal–metabolic risk modulation

    Research articlePrevention & lipids

  14. Eur Heart J Cardiovasc Pharmacother

    Bleeding risk assessment in patients with new-onset atrial fibrillation after coronary surgery: a proof-of-concept study

    Cohort studyArrhythmias & EP

  15. Eur Heart J Cardiovasc Pharmacother

    Longitudinal loop diuretic use in patients with HFrEF initiated with sodium–glucose cotransporter 2 inhibitors

    Cohort studyHeart failure

  16. Eur Heart J Cardiovasc Pharmacother

    Kidney function and acid–base status as gatekeepers of natriuretic and diuretic responsiveness in chronic HF: insights from the DEA-HF clinical trial

    Secondary analysisHeart failure

  17. Eur Heart J Cardiovasc Pharmacother

    Selective serotonin reuptake inhibitors and bleeding risk in patients undergoing PCI on dual antiplatelet therapy: a retrospective cohort study

    Cohort studyCoronary & ACS

  18. Eur Heart J Cardiovasc Pharmacother

    Abbreviated dual antiplatelet therapy after percutaneous coronary intervention with drug coated balloons in acute coronary syndromes: insights from the SWEDEHEART registry

    Cohort studyCoronary & ACS

  19. Eur Heart J Cardiovasc Pharmacother

    Effectiveness and safety of sodium-glucose cotransporter-2 inhibitor initiation in sacubitril-valsartan users with heart failure: a population-based cohort study

    Cohort studyHeart failure

  20. Eur Heart J Cardiovasc Pharmacother

    Effect of intensive blood pressure and blood glucose control on cardiovascular outcomes driven by reductions in cardiovascular death and nephropathy: win ratio analysis of ADVANCE trial

    Research articleHypertension

  21. Eur Heart J Cardiovasc Pharmacother

    Initiation of eplerenone vs. spironolactone and all-cause mortality in HFrEF: linked database study

    Cohort studyHeart failure

  22. Eur Heart J Cardiovasc Pharmacother

    Implementation of novel antithrombotic treatment strategies and outcome improvements in patients with myocardial infarction and atrial fibrillation over 20 years: a nationwide cohort study

    Cohort studyCoronary & ACS

  23. Eur Heart J Cardiovasc Pharmacother

    Monoclonal antibodies targeting IL-5/5R or IL-4/13 pathways in eosinophilic myocarditis: a single-centre experience and systematic literature review

    Cohort studyHeart failure

  24. Eur Heart J Cardiovasc Pharmacother

    Implementing sodium–glucose co-transporter 2 inhibitors in cardiovascular–kidney–metabolic syndrome: a multidisciplinary expert perspective

    Guideline or statementCardiometabolic & kidney

  25. Eur Heart J Cardiovasc Pharmacother

    Heart failure and tricuspid regurgitation: the role of SGLT2 inhibitors in improving outcomes

    Cohort studyHeart failure

  26. Eur Heart J Cardiovasc Pharmacother

    Impact of single vs. dual local anaesthetic regimen on the efficacy and safety of percutaneous stellate ganglion block for electrical storm: new insights from the STAR study

    Cohort studyArrhythmias & EP

  27. Eur Heart J Cardiovasc Pharmacother

    A Bayesian analysis of finerenone in heart failure with mildly reduced and preserved ejection fraction: a pre-specified analysis of FINEARTS-HF

    Secondary analysisHeart failure

  28. Eur Heart J Cardiovasc Pharmacother

    Net clinical benefit of extended dual pathway inhibition in chronic coronary syndrome as classified by the 2024 ESC criteria: a COMPASS substudy

    Cohort studyCoronary & ACS

  29. Eur Heart J Cardiovasc Pharmacother

    Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system

    Research articleCardio-oncology & other

  30. Eur Heart J Cardiovasc Pharmacother

    Effect of beta blockers in acute and chronic coronary syndromes without reduced ejection fraction: a landmark analysis from the REBOOT trial

    Secondary analysisCoronary & ACS

  31. Eur Heart J Cardiovasc Pharmacother

    Cardiovascular safety of 5α-reductase inhibitors in people with benign prostatic hyperplasia and type 2 diabetes: a propensity score-matched analysis

    Cohort studyCardiometabolic & kidney